Novartis AG
BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
Last updated:
Abstract:
The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
Status:
Application
Type:
Utility
Filling date:
12 Jun 2019
Issue date:
19 Dec 2019